Amniotic Fluid Stem Cell Spheroids for Urinary Incontinence Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for urinary incontinence, including physical rehabilitation and surgical methods, are limited in effectiveness, especially for the male population, and there is a need for a simple and effective therapy.
Innovation Solution
Administering a therapeutically effective amount of amniotic fluid stem cells, potentially combined with hyaluronic acid, to treat urinary incontinence, with the cells being administered as spheroids for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If physical rehabilitation is used to treat urinary incontinence, then the treatment is non-invasive and simple, but the therapeutic effect is limited
Solution Approach 1:
The patent introduces amniotic fluid stem cells as an intermediary substance to bridge the gap between simple non-invasive treatment and effective therapy. The stem cells are administered via injection into the urethral sphincter region, serving as a biological mediator that promotes tissue regeneration and improves sphincter function without requiring complex surgical procedures. This resolves the contradiction by providing a minimally invasive treatment with proven therapeutic efficacy.
2Reliability
If surgical treatment is used to treat urinary incontinence, then the success rate is high, but the procedure complexity increases and some patients refuse surgery
Solution Approach 1:
The patent extracts the essential therapeutic element (stem cells) from complex surgical procedures and delivers it through a simplified injection method. Instead of performing complex surgical operations to achieve high success rates, the invention isolates and administers amniotic fluid stem cells directly to the target tissue, maintaining therapeutic efficacy while dramatically reducing procedural complexity and patient burden.
3Ease of operation
If amniotic fluid stem cells are administered as individual cells, then the administration is simple, but the therapeutic effect is less significant compared to spheroids
Solution Approach 1:
The patent merges individual amniotic fluid stem cells into three-dimensional spheroid structures before administration. This combination approach enhances therapeutic efficacy by improving cell survival, proliferation, and functional integration at the injection site. The spheroid structure maintains relative administrative simplicity while significantly boosting the therapeutic effect compared to individual cell administration.
Data Source
AI summary
Disclosed herein is a use of an amniotic fluid stem cell spheroid in the preparation of a composition or pharmaceutical composition for treating urinary incontinence, wherein said pharmaceutical composition may further comprise hyaluronic acid.